Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 15;119(12):2291-9.
doi: 10.1002/cncr.27989. Epub 2013 Apr 11.

Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007

Affiliations

Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007

George Kurdgelashvili et al. Cancer. .

Abstract

Background: Population-based studies comprehensively describing incidence patterns of human papillomavirus (HPV)-related preinvasive and invasive neoplasms prior to widespread HPV vaccination are sparse.

Methods: Age-adjusted incidence rates (IRs), IR ratios (IRRs), and annual percent changes (APCs) in IRs were calculated for potentially HPV-related tumors diagnosed in the Surveillance, Epidemiology and End Results (SEER) Program during 1978 through 2007.

Results: Overall IRs for preinvasive tumors were significantly higher than for invasive squamous cell tumors of cervix (IRR = 3.42), vulva (IRR = 1.87), and vagina (IRR = 1.19) and significantly lower for adenomatous cervical tumors (IRR = 0.43), and squamous cell tumors of penis (IRR = 0.64), anus (males, IRR = 0.53; females, IRR = 0.14), and head and neck (H&N) (males, IRR = 0.01; females, IRR = 0.02). Incidence of preinvasive squamous tumors of cervix, vagina, and penis rose rapidly over time and decreased for invasive neoplasms. The most rapid increases occurred for preinvasive (males, APC = 16.0; females, APC = 7.3) and invasive anal tumors (males, APC = 3.6; females, APC = 2.3). IR patterns were generally similar among evaluable racial/ethnic groups, with the exception of H&N invasive tumor IRs which increased exclusively among white males.

Conclusions: Contrary to the opposing trends of preinvasive and invasive squamous tumors of cervix, vagina, and penis, preinvasive and invasive anal tumor IRs increased significantly over time by sex, age, and racial/ethnic groups. Successful HPV vaccination programs are needed to measurably reduce incidence of HPV-related neoplasms in the future, particularly for cancer sites with rising incidence rates for which effective screening modalities are limited. Cancer 2013;119:2291-2299. © 2013 American Cancer Society.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age-specific incidence rates of preinvasive and invasive adenomatous tumors of the cervix and squamous cell tumors of the cervix, vagina, vulva, penis, anus, and potentially HPV-related head and neck sites (H&N) diagnosed in SEER-9 during 1978–2007 by gender.
Figure 2
Figure 2
Age-adjusted trends of preinvasive and invasive adenomatous tumors of the cervix and squamous cell tumors of the cervix, vagina, vulva, penis, anus, and potentially HPV-related head and neck sites (H&N) diagnosed in SEER-9 during 1978–2007 by gender.
Figure 3
Figure 3
Age-adjusted trends of preinvasive and invasive adenomatous tumors of the cervix and squamous cell tumors of the cervix, vagina, vulva, penis, anus, and potentially HPV-related head and neck (H&N) sites diagnosed in SEER-9 during 1978–2007 by gender and age group. Note: There were too few cases of H&N tumors among males and females to plot.
Figure 4
Figure 4
Age-adjusted trends of preinvasive and invasive adenomatous tumors of the cervix and squamous cell tumors of the cervix, vagina, vulva, penis, anus, and potentially HPV-related head and neck (H&N) sites by gender diagnosed in SEER-9 during 1978–2007 for whites and blacks and in SEER-13 during 1992–2007 for Hispanics (white) and Asian/Pacific Islanders (APIs). Note: There were too few cases of H&N tumors among females to plot.

References

    1. US Food and Drug Administration. [accessed September 26, 2012];Approved products. Available at : http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm0....
    1. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011 Jun 18;377(9783):2085–2092. - PubMed
    1. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008 Nov 15;113(10 Suppl):3036–3046. - PMC - PubMed
    1. Copeland G, Datta SD, Spivak G, Garvin AD, Cote ML. Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985–2003. Cancer. 2008 Nov 15;113(10 Suppl):2946–2954. - PubMed
    1. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer. 2008 Nov 15;113(10 Suppl):2892–2900. - PMC - PubMed

Publication types

MeSH terms